Yu.O. Senko

Yu.O. Senko

Auto-generated profile, based on publicly available information

Yu.O. Senko

SI “National scientific center of phthisiology, pulmonology and allergology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Tuberculosis, Lung Diseases, HIV Infection
Verified
Journal Article
Closed access
PDF file
YFYu.I. Feshchenko
Yu.I. Feshchenko
NLN.A. Litvinenko
N.A. Litvinenko
NGN.V. Grankina
N.V. Grankina
MPM.V. Pogrebna
M.V. Pogrebna
YSYu.O. Senko
Yu.O. Senko
ЮФЮ.і. Фещенко
Ю.і. Фещенко
Objective — to study the effectiveness of treatment of MDR-TB (multidrug-resistant tuberculosis) and preXDR-TB/XDR-TB (pre-extensively and extensively drug resistant tuberculosis), depending on the composition of ITRs (individualized treatment regimens). Materials and methods. Тhe prospective observational study included 566 patients with MDR/preXDR-TB and XDR-TB during 2016—2020 on the scientific clinical bases of the SI «National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine» and ME «Kryvyi Rih Anti-tuberculosis Dispensary» Dnipropetrovsk Regional Council Department. Patients were prescribed individualized treatment regimens in cases where short (standard or modified) regimens could not be prescribed. Patients were divided into comparison groups: 469 of them were treated with antimycobacterial therapy including bedaquiline and other effective antimycobacterial drugs groups A—C (without delamanid) — group 1. And 97 patients who were treated with the inclusion of both new antimycobacterial drugs (bedaquiline and delamanid) — group 2. Results and discussion. Regardless of whether the delamanid, in addition to bedaquiline and other drugs selected for the scheme according to WHO recommendations, «effective treatment» was found in 91.3 against 88.6 % of patients. In the remote period (6-month — 4-year follow-up period) there was no recurrence of the disease, regardless of the composition of the regime. The loss of treatment effectiveness was due to deaths from non-tuberculosis reasons and those lost for follow-up. Conclusions. For highly effective treatment, individualized regimens should include bedaquidine and linezolid from group A, and for previously ineffectively treated patients, clofazimine and carbapenems must be included (possibility to include 4 or more effective AMDs in ITR). For patients with fluoroquinolone resistance, treatment should include delamanid.

15 March 2023 in Tuberculosis, Lung Diseases, HIV Infection
Verified
Journal Article
Open access
PDF file
YFYu.I. Feshchenko
Yu.I. Feshchenko
NLN.A. Lytvynenko
N.A. Lytvynenko
MPM.V. Pohrebna
M.V. Pohrebna
YSYu.O. Senko
Yu.O. Senko
ALA.S. Lafeta
A.S. Lafeta
YTYa.S. Terleeva
Ya.S. Terleeva
Мета роботи — вивчити програмні результати ефективності та переносності стандартної комбінації режиму BPaL (NIX-TB, zeNIX-TB, TB Practecal, Simplici TB) для хворих на туберкульоз із пре-широ­кою лікарською стійкістю та невдач лікування туберкульозу з множинною лікарською стійкістю в операційному дослідженні. Матеріали та методи. Лікування хворих за режимом BPaL проведено в межах проєкту МБФ «Орга­нізація оптимальних технологій у сфері охорони здоров’я» на базі Національного інституту фтизіат­рії і пульмонології імені Ф.Г. Яновського НАМН України як операційне дослідження «Пілотне дослід­ження з оцінки ефективності та безпечності антимікобактеріальної терапії BPaL в Україні». Набір тривав з листопада 2020 до березня 2022 року. Склад режиму BPaL: бедаквілін — 400 мг щоденно перших 2 тиж із наступним переходом на 200 мг через день, лінезолід — 1200 мг щоденно (з можливістю зміни дози чи відміни не раніше ніж через 4 послідовних тижні його використання), претоманід — 200 мг щоденно. Стандартна тривалість лікування — 6 міс (26 тиж або 182 дози). Тривалість лікування збільшували до 9 міс у разі позитивного результату посіву мокротиння (або реверсії) через 4 міс лікування та недостатньої динаміки через 6 міс лікування. План впровадження передбачав 135 хворих на туберкульоз із пре-широкою лікарською стійкістю або невдачею попередніх курсів без критеріїв вилучення. Результати та обговорення. Незважаючи на суттєві виклики/бар’єри, що виникли на шляху реалізації операційного дослідження, ефективність режиму BPaL, виявлена в межах проєкту, узгоджується з результатами клінічних випробувань різних варіантів режиму BPaL: успішним лікування було у 91,5 % хворих. Режим був досить безпечним: повна відміна BPaL через серйозні небажані явища (НЯ) лише у 4 хворих. Решті пацієнтів, незважаючи на НЯ різного ступеня у 81,4 % хворих, вдалося успішно завершити BPaL. Повну відміну лінезоліду зі складу BPaL проведено лише у 8,2 % хворих. Очікувано, що основними НЯ були мієлосупресія та периферична нейропатія (основні НЯ лінезоліду у високій дозі — 1200 мг/добу). Також зафіксовано гепатотоксичність майже у кожного 4-го пацієнта. Отримані нами дані узгоджуються з результатами клінічних випробувань. Таких високих результатів вдалося досягти завдяки тісній співпраці партнерів, підготовці та навчанню спеціалістів інституту, як наслідок — уважне ставлення до кожного пацієнта, ретельний моніторинг його стану та людино-орієнтований підхід. Висновки. Україна є першою країною у світі, яка провела лікування хворих на ТБ за режимом BPaL у межах операційних досліджень з гарними результатами, що сприяло ширшому використанню лікування за режимом BPaL в Україні навіть під час війни.

28 June 2025 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
YFYu.I. Feshchenko
Yu.I. Feshchenko
NLN.A. Lytvynenko
N.A. Lytvynenko
LPL.M. Protsyk
L.M. Protsyk
MPM.V. Pohrebna
M.V. Pohrebna
YSYu.O. Senko
Yu.O. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for selecting the optimal 6-month treatment regimen for patients with multidrugresistant TB (MDR-TB) and pre-extensively drug-resistant TB (pre-XDR-TB) based on an analysis of efficacy, safety, and costeffectiveness. MATERIALS AND METHODS. The study included 337 patients who were prescribed one of four regimens: BPaLM, BPaL, BdqLzdMfxhdCsDlm, or BdqLzdCfz(Mrp)CsDlm. Efficacy, adverse reactions, and treatment costs were evaluated. RESULTS AND DISCUSSION. The highest efficacy (100 %) was demonstrated by the BPaLM regimen. The BPaL regimen was optimal for pre-XDR-TB. The 6-month BdqLzdMfxhdCsDlm and BdqLzdCfz(Mrp)CsDlm regimens are appropriate when Pa-based regimens cannot be used or are limited (e.g., in children under 14 years, pregnant women, in cases of resistance or intolerance to Pa or Lzd). The developed algorithms for assigning various 6-month short-term chemotherapy regimens allow for individualized treatment selection based on Mycobacterium tuberculosis drug susceptibility, comorbidities, potential toxicity, and drug availability, contributing to improved treatment efficacy and reduced failure risk. CONCLUSIONS. The BPaLM regimen is the standard treatment for patients with rifampicin-resistant TB / MDR-TB. For patients with pre-XDR-TB, the BPaL regimen offers the best balance of efficacy, tolerability, and cost-effectiveness. The proposed prescription algorithms enable a personalized treatment approach and improve therapeutic outcomes.

28 December 2022 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
NLN.A. Lytvynenko
N.A. Lytvynenko
MPM.V. Pogrebna
M.V. Pogrebna
YSYu.O. Senko
Yu.O. Senko
LPL.M. Protsyk
L.M. Protsyk
SKS.P. Korotchenko
S.P. Korotchenko
RLR.L. Liubevych
R.L. Liubevych
BACKGROUND. Often in practice there are combinations of several diseases, or tuberculosis of the respiratory organs develops against the background of various comorbidities, including HIV. OBJECTIVE. To demonstrate best clinical practices for selecting the optimal individualized treatment regimen (ITR) in a patient with multidrug-resistant tuberculosis (MDR-TB) associated with HIV in the setting of severe immunosuppression and complicated by poor tolerability. MATERIALS AND METHODS. Presented clinical analysis of newly diagnosed generalized MDR-TB associated with HIV, treated for ITR for 9 months, which was assigned according to the World Health Organization step-by-step algorithm based on phenotypic drug susceptibility testing data. At the time of assessment, the patient was taking 273 doses of ITR. ITR required extended monitoring and selection during its first months of treatment, as it was accompanied by severe intolerance to antimycobacterial drugs. RESULTS AND DISCUSSION. The expressed adverse events of 3-4 degrees were managed at the expense of carrying out the strengthened clinical and laboratory monitoring and consultations of narrow experts that allowed to select optimum ITR and in addition to carry out symptomatic treatment. Such tactics led to the normalization of hematological parameters with the disappearance of clinical manifestations of other adverse events and provided high intermediate results of treatment at the 9th month of ITR. Steady negativity of smear and culture (from1st month of treatment), positive radiological dynamics and significant improvement of well-being were obtained. CONCLUSIONS. Management of patients with MDR-TB/HIV co-infection with severe immunosuppression in patients who are treated by ITR requires enhanced monitoring of adverse reactions and rapid changes in the composition of ITR and early symptomatic treatment to ensure better adherence to treatment and positive outcomes.

28 June 2025 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
YFYu.I. Feshchenko
Yu.I. Feshchenko
NLN.A. Lytvynenko
N.A. Lytvynenko
LPL.M. Protsyk
L.M. Protsyk
MPM.V. Pohrebna
M.V. Pohrebna
YSYu.O. Senko
Yu.O. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for selecting the optimal 6-month treatment regimen for patients with multidrugresistant TB (MDR-TB) and pre-extensively drug-resistant TB (pre-XDR-TB) based on an analysis of efficacy, safety, and costeffectiveness. MATERIALS AND METHODS. The study included 337 patients who were prescribed one of four regimens: BPaLM, BPaL, BdqLzdMfxhdCsDlm, or BdqLzdCfz(Mrp)CsDlm. Efficacy, adverse reactions, and treatment costs were evaluated. RESULTS AND DISCUSSION. The highest efficacy (100 %) was demonstrated by the BPaLM regimen. The BPaL regimen was optimal for pre-XDR-TB. The 6-month BdqLzdMfxhdCsDlm and BdqLzdCfz(Mrp)CsDlm regimens are appropriate when Pa-based regimens cannot be used or are limited (e.g., in children under 14 years, pregnant women, in cases of resistance or intolerance to Pa or Lzd). The developed algorithms for assigning various 6-month short-term chemotherapy regimens allow for individualized treatment selection based on Mycobacterium tuberculosis drug susceptibility, comorbidities, potential toxicity, and drug availability, contributing to improved treatment efficacy and reduced failure risk. CONCLUSIONS. The BPaLM regimen is the standard treatment for patients with rifampicin-resistant TB / MDR-TB. For patients with pre-XDR-TB, the BPaL regimen offers the best balance of efficacy, tolerability, and cost-effectiveness. The proposed prescription algorithms enable a personalized treatment approach and improve therapeutic outcomes.

30 October 2025 in Tuberculosis, Lung Diseases, HIV Infection
Verified
Journal Article
Open access
PDF file
NLN.A. Lytvynenko
N.A. Lytvynenko
LPL.M. Protsyk
L.M. Protsyk
MPM.V. Pohrebna
M.V. Pohrebna
YSYu.O. Senko
Yu.O. Senko
Objective — to investigate the impact of comorbidities and adverse events (AEs) on the effectiveness of short-course treatment regimens for drug-resistant tuberculosis (DR-TB) and patients’ quality of life during the war in Ukraine. Materials and methods. The study included 337 patients with DR-TB (123 with multidrug-resistant TB (MDR-TB) and 214 with pre-extensively drug-resistant TB (pre-XDR-TB)) who received 6—9-month treatment regimens (BdqLzdMfxhdCsDlm, BPaLM, BPaL, BdqLzdCfz(Mrp)CsDlm) from January 2022 to December 2024. Results and discussion. In the MDR-TB group, the BPaLM regimen demonstrated a significantly better safety profile compared with BdqLzdMfxhdCsDlm: comorbidities and adverse events (AEs/serious AEs) were observed in 14.9 vs 31.7 % of cases, while severe AEs (≥ Grade 3) in 4.3 vs 15.8 %, respectively (p < 0.05). The most frequently reported reactions were neurological (10.5 %), haematological (9.2 %) and hepatotoxic (7.9 %), predominantly occurring in the 2nd—3rd months of treatment. In the pre-XDR-TB group, the BPaL regimen was associated with a higher AE/serious AE incidence (55.4 vs 28.3 % for BdqLzdCfz(Mrp)CsDlm, p < 0.001) and severe AEs (48.2 vs 17.4 %, p < 0.001). The most common complications with BPaL were haematological (27.4 %), neurological (21.4 %) and hepatotoxic (14.9 %) reactions, linked to high-dose linezolid (1200 mg/day). Conclusions. The BPaLM regimen is the preferred option for MDR-TB treatment due to its lower AE incidence and better safety profile compared with BdqLzdMfxhdCsDlm. For pre-XDR-TB, the BPaL regimen is associated with a higher AE frequency due to dose-dependent linezolid toxicity. Dose optimisation and careful monitoring during the early stages of therapy are critical for improving treatment efficacy and safety in wartime conditions.